Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab formulation comparison in postmenopausal osteoporosis
NCT02016716Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2013
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started Dec 2013; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT02016716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016716.